AgingResearch.NewsJoin free

Phase 3Active, not recruiting

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)

A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial

Sponsor
Eli Lilly and Company (Industry)
Enrollment
250 planned
Conditions
Obesity; Overweight
Interventions
Retatrutide; Placebo
Ages
adults, older adults
Registry
NCT07232719

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

Primary outcomes

  • Percent Change from Baseline in Body Weight

History

  1. Primary completion expected

  2. Last registry update

  3. Registered

  4. Started

In the news

TrialsMedical Xpress (opens Medical Xpress in a new tab)

Lilly’s retatrutide at least halves knee osteoarthritis pain in two-thirds of participants

Two Northwestern-led phase 3 trials enrolled over 1,000 adults with overweight or obesity; 38% on placebo achieved comparable pain relief, while the highest dose produced roughly 25% weight loss.

Also in NEJM (opens NEJM in a new tab), Yonhap News Agency (opens Yonhap News Agency in a new tab)

TrialsSTAT+ (opens STAT in a new tab, subscription)

Eli Lilly says retatrutide lowers blood sugar and weight more than Ozempic in diabetes

The large head-to-head study tested Lilly’s investigational incretin injection against Novo Nordisk’s drug.

Also in Endpoints News (opens Endpoints News in a new tab), BioPharma Dive (opens BioPharma Dive in a new tab), ByDrug (opens ByDrug in a new tab), Diario Médico (opens Diario Médico in a new tab), asiae.co.kr (opens asiae.co.kr in a new tab), oe24 (opens oe24 in a new tab)